Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4143390-A4143390, November 12, 2024. Introduction:Obesity is rising in prevalence worldwide and co-exists in patients with group 1 pulmonary hypertension (PH). Despite having group 1 PH, pulmonary capillary wedge pressure (PCWP) was higher with obesity (13.8 ± 6.3 vs 9.4 ± 7.7

Obesity 40

Obesity Pulmonary Hypertension Diabetes 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142839-A4142839, November 12, 2024. Introduction:Inflammation is a key driver in the development of pulmonary arterial hypertension (PAH). The pulmonary vasculature was evaluated histologically. of which are fungi.

Pulmonary 40

Pulmonary Hypertension Innovation Exercise 40

Journal of the American Heart Association

MARCH 7, 2025

BackgroundLifethreatening pulmonary arterial hypertension (PAH) still lacks a direct therapeutic approach targeted to the molecular defects associated with the disease. Journal of the American Heart Association, Ahead of Print. No effect of rimeporide was detected in control rats.

Pulmonary 45

Pulmonary Hypertension Circulation 45

Circulation

MAY 27, 2024

Circulation, Volume 149, Issue 22 , Page 1770-1774, May 28, 2024.

Pulmonary 45

Pulmonary Hypertension Circulation 45

Circulation

FEBRUARY 5, 2024

Circulation, Ahead of Print. BACKGROUND:Pulmonary hypertension (PH) is a progressive cardiopulmonary disease with a high mortality rate. Small hairpin RNA and ME1 enzymatic inhibitor (ME1*) were used to study the mechanism of ME1 in pulmonary artery endothelial cells.

Pulmonary 45

Pulmonary Hypertension Pharmacology Circulation 45

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4117657-A4117657, November 12, 2024. Background:Primary pulmonary arterial hypertension (PAH) is a disease affecting young subjects. It has very poor prognosis and optimal treatment is not available.

Pulmonary 40

Pulmonary Hypertension Blood Pressure Pharmacology 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4141118-A4141118, November 12, 2024. Objective:Pulmonary Arterial Hypertension (PAH) is a fatal disease with high mortality rates and late diagnosis, currently lacking complete cure. ng/ml; idiopathic pulmonary arterial hypertension group: 5.28 ± 0.77

Pulmonary 40

Pulmonary Hypertension Heart Failure Circulation 40

Circulation

APRIL 6, 2025

Circulation, Volume 151, Issue 14 , Page e921-e921, April 8, 2025.

Pulmonary 45

Pulmonary Hypertension Circulation 45

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146445-A4146445, November 12, 2024. Rationale:Previously we identified a mouse modelTie2Cre-mediated disruption ofEgln1of Pulmonary arterial hypertension (PAH) with progressive obliterative vascular remodeling including vascular occlusion and plexiform-like lesions and right heart failure.

Pulmonary 40

Pulmonary Hypertension Heart Failure Circulation 40

Heart BMJ

MARCH 22, 2024

Objective In Fontan circulation, pulmonary arterial hypertension (PAH)-targeted therapies could improve the patients’ exercise capacity. This study aimed to investigate the effects of PAH agents on different exercise parameters in stable Fontan patients by synthesising evidence of randomised controlled trials (RCTs).

Exercise 40

Exercise Circulation Pulmonary Pharmacology 40

Circulation: Cardiovascular Imaging

FEBRUARY 25, 2025

Circulation: Cardiovascular Imaging, Ahead of Print.

Pulmonary 40

Pulmonary Cardiovascular Imaging Hypertension Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4144785-A4144785, November 12, 2024. Background:Acquired mitochondrial dysfunction is one of the characteristics of pulmonary arterial hypertension (PAH). Single-cell analysis showed that ARMCX3 was highly expressed in pulmonary vascular smooth muscle cells and endothelial cells.

Biomarkers 40

Biomarkers Pulmonary Hypertension Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4143405-A4143405, November 12, 2024. Background:Pulmonary hypertension (PH) and secondary right ventricle dysfunction is present in 20% of adults with coarctation of aorta (COA) based on echocardiographic studies.

Pulmonary 40

Pulmonary Hypertension Outcomes Atrial Fibrillation 40

Journal of the American Heart Association

NOVEMBER 28, 2023

BackgroundPulmonary artery hypertension (PAH) is a fatal disease characterized by a complex pathogenesis. Transpulmonary exosomal miRs offer valuable insights into pulmonary circulation microenvironments. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Pulmonary Heart Disease 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4144822-A4144822, November 12, 2024. Multivariable Cox regression analyses were constructed to assess the relationship between AG and short-term outcomes in sepsis patients complicated by PH.Results:2012 sepsis patients with pulmonary hypertension were included.

Pulmonary 40

Pulmonary ICU Hypertension Hospital 40

Circulation

JUNE 9, 2024

Circulation, Volume 149, Issue 24 , Page e1412-e1412, June 11, 2024.

Pulmonary 45

Pulmonary Angioplasty Hypertension Circulation 45

Circulation

MAY 12, 2024

Circulation, Volume 149, Issue 20 , Page 1565-1567, May 14, 2024.

Pulmonary 45

Pulmonary Hypertension Circulation 45

Circulation

MARCH 16, 2025

Circulation, Volume 151, Issue 11 , Page e763-e763, March 18, 2025.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 45

Circulation

APRIL 25, 2024

Circulation, Ahead of Print. Unfortunately, patients will often present late in their disease course with severe right-sided heart failure, pulmonary hypertension, and life-limiting symptoms that have few durable treatment options.

Tricuspid 80

Tricuspid Pacemaker Heart Failure Pulmonary 80

Circulation: Cardiovascular Imaging

MARCH 13, 2025

Circulation: Cardiovascular Imaging, Ahead of Print. Very preterm-born young adults are at risk for developing pulmonary arterial (PA) hypertension later in life. An early sign of PA hypertension is increased PA stiffness. An early sign of PA hypertension is increased PA stiffness. m/s [1.453.05] versus 1.61

Pulmonary 40

Pulmonary Hypertension Cardiovascular Imaging Circulation 40

Dr. S. Venkatesan MD

APRIL 28, 2024

Both atria develop from a combination of the primitive atrium, sinus venous, and pulmonary veins.It However, underlying lesions such as hypertension, mitral valve disease, COPD, ASD, and TR greatly influence the degree of atrial enlargement. But, we rarely dispute it , & ask which atrium dilates more in AF ? Let us see few factors.

Atrial Fibrillation 75

Atrial Fibrillation Bicuspid/Mitral Pulmonary Ablation 75

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4135252-A4135252, November 12, 2024. Background:Pulmonary hypertension (PH) is a major contributor to cardiovascular disease-related morbidity and mortality.

Myocardial Infarction 40

Myocardial Infarction Hospital Hypertension Pulmonary 40

Circulation

JANUARY 26, 2025

Circulation, Volume 151, Issue 4 , Page e32-e32, January 28, 2025.

Article 49

Article Pulmonary Circulation Hypertension 49

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4122350-A4122350, November 12, 2024. Pulmonary vein thrombi (PVTs) are common and are underestimated. Background:Retrieved thrombus studies have shown that retrieved thrombi have calcifications, indicating that the thrombi are old. In 2022, we reported that 98.6% from 50 y.o.

Pulmonary 45

Pulmonary Diabetes Atrial Fibrillation Hypertension 45

Circulation

NOVEMBER 24, 2024

Circulation, Volume 150, Issue 22 , Page e467-e467, November 26, 2024.

Article 45

Article Pulmonary Hypertension Circulation 45

Circulation

MARCH 9, 2025

Circulation, Volume 151, Issue 10 , Page e686-e686, March 11, 2025.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Article Heart Failure Pulmonary 45

Circulation: Heart Failure

MARCH 5, 2025

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Exercise-induced hypertension (EIH) is common in adults with coarctation of the aorta (COA), but there are limited data about hemodynamics and outcomes in such patients.

Exercise 40

Exercise Hypertension Outcomes Biomarkers 40

Circulation

JANUARY 26, 2025

Circulation, Volume 151, Issue 4 , Page e31-e31, January 28, 2025.

Article 45

Article Pulmonary Hypertension Circulation 45

Circulation

NOVEMBER 12, 2023

Circulation, Ahead of Print.

Pulmonary 40

Pulmonary Hypertension Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139791-A4139791, November 12, 2024. vs. Ctrl), indicative of pulmonary congestion. We evaluated the presence of HFpEF hallmark and corroborated our data with literature. l) for 8 weeks. Cardiac hypertrophy was confirmed by increased heart weight (p<0.01

Preserved Ejection Fraction 40

Preserved Ejection Fraction Hypertension Blood Pressure Obesity 40

All About Cardiovascular System and Disorders

MARCH 26, 2024

Transcript of the video: Eisenmenger syndrome is an important complication of large left to right shunts which develop later due to development of pulmonary vascular obstructive disease and severe pulmonary hypertension. So in ASD Eisemenger, suprasystemic pulmonary hypertension is possible. But, leave that alone.

VSD 52

VSD Pulmonary Hemorrhage Hypertension 52

Dr. S. Venkatesan MD

AUGUST 3, 2024

However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. This may be correct when there is acute raise in RV after load, as in PE.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Pulmonary Heart Dysfunction 52

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142484-A4142484, November 12, 2024. Background:Pulmonary arterial hypertension (PAH) is characterized by an elevation in pulmonary vascular resistance and arterial pressure, culminating in right ventricular failure and mortality.

Pulmonary 40

Pulmonary Hypertension Biomarkers Circulation 40

BoardVitals - Cardiovascular

JUNE 14, 2017

In preparation for the ABIM Cardiovascular Disease exam, check out the BoardVitals Cardiology Board Review Question Bank and we’ll make sure you’re well versed in the following 13 areas covered on the exam: Multiple-Choice Component Arrhythmias 15% Coronary Artery Disease 23% Heart Failure and Cardiomyopathy 17% Valvular Disease 15% Pericardial (..)

Congenital Heart Disease 52

Congenital Heart Disease Coronary Angiogram Coronary Artery Disease Cardiovascular Disease 52

BoardVitals - Cardiovascular

JULY 26, 2022

Heart Failure and Cardiomyopathy 19% Valvular Disease 15% Pericardial Disease 3% Congenital Heart Disease 3% Vascular Diseases 5% Systemic Hypertension and Hypotension 8.5% The exam covers the following topics: Arrhythmias 15% Coronary Artery Disease 21.5%

Congenital Heart Disease 52

Congenital Heart Disease Certification Coronary Artery Disease Congenital 52

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4123391-A4123391, November 12, 2024. The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiomyopathy Heart Failure Pulmonary 40

All About Cardiovascular System and Disorders

APRIL 14, 2024

Some of the other useful parameters are mitral E velocity deceleration time, changes in mitral inflow with Valsalva maneuver, mitral L velocity, isovolumic relaxation time, left atrial maximum volume index, pulmonary vein systolic/diastolic velocity ratio, color M-mode Vp and E/Vp ratio. Circulation. References Beaudoin J et al.

Bicuspid/Mitral 52

Bicuspid/Mitral Pulmonary Atrial Fibrillation Ultrasound 52